Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

Study identifier:D4320C00017

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Double-blind, Double-dummy, Placebo-controlled, Randomised, Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years.

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

ZD4054, ZD4054, ZD4054, ZD4054, Moxifloxacin, ZD4054 Placebo, ZD4054 Placebo, Moxifloxacin placebo, Moxifloxacin placebo, Moxifloxacin placebo, ZD4054 Placebo, ZD4054, ZD4054

Sex

Male

Actual enrollment

40

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jun 2008
Primary Completion Date: -
Study Completion Date: 01 Nov 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria